Drug Trial Radar · NCT06873516
Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)
Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
182
Actual
Start
Mar 20, 2025
Primary completion
May 29, 2026
Study completion Jun 5, 2026
Sponsor
- Lead sponsor
- Evommune, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU).
Conditions
- Chronic Spontaneous Urticaria
Interventions
EVO756Drug
Dose 1
EVO756Drug
Dose 2
EVO756Drug
Dose 3
Placebo controlDrug
Placebo control
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from baseline in UAS7Time frame: Week 12
Locations
53 sites in 3 countries. Site status is shown where the registry gives one.
Cahaba Dermatology Skin Health Center
Birmingham, Alabama
Velocity Clinical Research, Mobile
Mobile, Alabama
Center for Dermatology Clinical Research
Fremont, California
Antelope Valley Clinical Trials
Lancaster, California
Northridge Clinical Trials
Northridge, California
NorthBay Clinical Research
Santa Rosa, California
Integrated Research of Inland
Upland, California
FOMAT Medical Research
Ventura, California
AMR Fort Myers
Fort Myers, Florida
Advanced Clinical Research Institute
Tampa, Florida
Sneeze, Wheeze & Itch Associates LLC
Normal, Illinois
The Indiana Clinical Trials Center
Plainfield, Indiana
The Iowa Clinic
West Des Moines, Iowa
Hutchinson Clinic
Hutchinson, Kansas
Bluegrass Allergy Care
Lexington, Kentucky
Delricht Research Louisville
Louisville, Kentucky
Delricht Research Louisiana
Baton Rouge, Louisiana
Velocity Clinical Research, Lafayette
Lafayette, Louisiana
Delricht Research
New Orleans, Louisiana
Johns Hopkins Bayview Medical Center
Baltimore, Maryland
Boston Specialists
Boston, Massachusetts
MI Skin Innovations
Northville, Michigan
DelRicht Research - Town Center Dermatology
Wildwood, Missouri
Vitality Clinical Trials
Woodbury, New York
Allergy Partners Clinical Research
Asheville, North Carolina
Delricht Research - Priority Care
Charlotte, North Carolina
Piedmont Healthcare
Statesville, North Carolina
Optima Research Boardman
Boardman, Ohio
DOCS Dermatology Research
Canal Winchester, Ohio
Bernstein Clinical Research Center
Cincinnati, Ohio
Toledo Institute of Clinical Research
Toledo, Ohio
AMR Myrtle Beach
Myrtle Beach, South Carolina
National Allergy and Asthma Research
North Charleston, South Carolina
Delricht Research Smyrna
Smyrna, Tennessee
Austin Regional Clinic ARC Clinical Research
Austin, Texas
Studies in Dermatology
Cypress, Texas
Western Sky Medical Research
El Paso, Texas
Delricht Research - Lockhard Matter Dermatology
Prosper, Texas
AMR Utah
Layton, Utah
Seattle Clinical Research Center
Seattle, Washington
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.